Drug Profile
Research programme: antibody-drug nanocell conjugates - EnGeneIC
Alternative Names: EGFREDVEnG Prop DrugLatest Information Update: 28 Jun 2020
Price :
$50
*
At a glance
- Originator EnGeneIC
- Class Antineoplastics; Bispecific antibodies; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jun 2020 No recent reports of development identified for preclinical development in Cancer in Australia (IV)
- 20 May 2016 Preclinical trials in Cancer in Australia (IV)